Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity
Copyright policy )Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity
Objective: Homozygous familial hypercholesterolemia is a rare disease usually caused by LDLR (low-density lipoprotein receptor) mutations. Homozygous familial hypercholesterolemia is characterized by markedly elevated LDL-C (low-density lipoprotein cholesterol) levels and an extremely high risk of premature atherosclerotic cardiovascular disease. A phase 2, proof-of-concept study (NCT02265952) demonstrated that evinacumab, a fully human monoclonal antibody to ANGPTL3 (angiopoietin-like 3 protein), reduced LDL-C levels in 9 patients with genotypically confirmed homozygous familial hypercholesterolemia and was well tolerated. The aim of this study was to analyze the effects of evinacumab on LDLR activity in lymphocytes purified from patients in the proof-of-concept study. Approach and Results: LDLR activity was assessed in patient lymphocytes before and after treatment with evinacumab and versus lymphocytes carrying wild-type LDLR, and also in an LDLR-defective Chinese hamster ovary cell line (CHO- ldl A7) transfected with plasmids encoding the LDLR variants. Overall mean peak reduction in LDL-C with evinacumab was −58±18%, occurring between Week 4 and Week 12. Mutations identified in the 9 patients were shown to be pathogenic, with loss of LDLR activity versus wild type. Two of the LDLR variants, p.(Cys681*) and p.(Ala627Profs*38), were class 2 type mutations that are retained in the endoplasmic reticulum. Six variants were class 3 type mutations with impaired LDL-C binding activity: p.(Trp87Gly), occurring in 2 patients, p.(Gln254Pro), p.(Ser177Leu), p.(Gly335Val), and p.(Ser306Leu). Evinacumab had no effect on LDLR activity. Conclusions: These results suggest that evinacumab is effective for lowering LDL-C in patients with homozygous familial hypercholesterolemia, and the inhibition of ANGPTL3 in humans lowers LDL-C in a mechanism independent of the LDLR.
Adult, Male, Adolescent, Lipoproteins, Hypercholesterolemia, rare disease, CHO Cells, Proof of Concept Study, Hyperlipoproteinemia Type II, Young Adult, Cricetulus, Animals, Humans, Point Mutation, Lymphocytes, gene, Frameshift Mutation, angptl3, Angiopoietin-Like Protein 3, pcsk9, hypercholesterolemia, Basic Sciences, Antibodies, Monoclonal, Proof of concept study, transmembrane domain, Cholesterol, LDL, Middle Aged, mutations, amg 145, inhibition, lipoproteins, Angiopoietin-like Proteins, evolocumab, Receptors, LDL, proof of concept study, monoclonal-antibody, Female, double-blind, Rare disease, Mutations
Adult, Male, Adolescent, Lipoproteins, Hypercholesterolemia, rare disease, CHO Cells, Proof of Concept Study, Hyperlipoproteinemia Type II, Young Adult, Cricetulus, Animals, Humans, Point Mutation, Lymphocytes, gene, Frameshift Mutation, angptl3, Angiopoietin-Like Protein 3, pcsk9, hypercholesterolemia, Basic Sciences, Antibodies, Monoclonal, Proof of concept study, transmembrane domain, Cholesterol, LDL, Middle Aged, mutations, amg 145, inhibition, lipoproteins, Angiopoietin-like Proteins, evolocumab, Receptors, LDL, proof of concept study, monoclonal-antibody, Female, double-blind, Rare disease, Mutations
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).62 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!